journal article·2021-03-10

One-Pot Preparation of Peptide-Doped Metal–Amino Acid Framework for General Encapsulation and Targeted Delivery

Benson Peter Mugaka, Sheng Zhang, Rui-Qi Li, Yu Ma, Bo Wang, Jin Hong, Yi-Hui Hu, Ya Ding, Xing-Hua Xia

Publisher page

Abstract

Metal–organic frameworks (MOFs), especially those made by biological molecules (bio-MOFs), have been proved to be prospective candidates for biomedical applications. However, a simple and universal bio-MOF to load different substances for precise targeting is still lacking. In this work, we propose a facile one-pot method to prepare a peptide-doped bio-MOF for general encapsulation and targeted delivery. This bio-MOF is constructed by 9-fluorenylmethyloxycarbonyl-modified histidine (Fmoc-His) as a bridging linker that coordinates with Zn2+ ions, denoted as ZFH. The Fmoc-His-Asp-Gly-Arg peptide (Fmoc-HDGR) can be easily doped into the ZFH structure with different ratios to modulate the targeting ability of ZFH-DGR. Containing both hydrophobic Fmoc and hydrophilic His moieties, this framework is compatible with encapsulating various types of payloads, including hydrophobic chemotherapeutic, hydrophilic protein, and positively/negatively charged inorganic nanoparticles. It has also been proved to be highly biocompatible and stable in circulation, exhibit the capabilities to target ανβ3 integrin overexpressed on tumor cells, and trigger drug release in a low pH microenvironment at the tumor site. As a proof of concept, Doxorubicin (Dox)-loaded ZFH-DGR (ZFH-DGR/Dox) demonstrated high cell selectivity between liver hepatocellular carcinoma (HepG2) cells and normal liver (L02) cells, which express high and low ανβ3 integrin, respectively. This selectivity endows ZFH-DGR/Dox precise treatment and low toxicity in Heps-bearing liver cancer mice. This work develops a de novo approach to construct a peptide-doped bio-MOF system for universal load, precise delivery, and peptide drug combination therapy in the future.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Peptidase Inhibition and Analysis · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 210009, China

Key Laboratory of Biomedical Functional Materials, School of Sciences, Ministry of Education, China Pharmaceutical University, Nanjing 211198, China

Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, The Institute for Biomedical Engineering & Nano Science, School of Medicine, Tongji University, Shanghai 200092, China

State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

Funding

Ministry of Education of the People's Republic of China · Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Double First-Class University Plan

References (37)

Show source-provided references
1. 10.1039/c0nj00275e10.1039/c0nj00275e ↗
2. 10.1038/ncomms275710.1038/ncomms2757 ↗
3. 10.1002/anie.20150434610.1002/anie.201504346 ↗
4. 10.1039/B618320B10.1039/B618320B ↗
5. 10.1039/b804302g10.1039/b804302g ↗
6. 10.1021/cr400392k10.1021/cr400392k ↗
7. 10.1016/j.ccr.2017.07.01210.1016/j.ccr.2017.07.012 ↗
8. 10.1002/adfm.20191008410.1002/adfm.201910084 ↗
9. 10.1021/acsami.8b1197210.1021/acsami.8b11972 ↗
10. 10.1021/jacs.0c0018810.1021/jacs.0c00188 ↗
11. 10.1021/jacs.5b1172010.1021/jacs.5b11720 ↗
12. 10.1039/D0NR04860G10.1039/D0NR04860G ↗
13. 10.1002/anie.20200747410.1002/anie.202007474 ↗
14. 10.1002/smll.20200125110.1002/smll.202001251 ↗
15. 10.1021/jacs.6b1193410.1021/jacs.6b11934 ↗
16. 10.1002/anie.20200029910.1002/anie.202000299 ↗
17. 10.1021/acs.analchem.0c0078210.1021/acs.analchem.0c00782 ↗
18. 10.1126/sciadv.aaz610810.1126/sciadv.aaz6108 ↗
19. 10.1002/smll.20200401610.1002/smll.202004016 ↗
20. 10.1039/C7DT04116K10.1039/C7DT04116K ↗
21. 10.1002/smll.20200098010.1002/smll.202000980 ↗
22. 10.1016/j.envres.2019.05.01910.1016/j.envres.2019.05.019 ↗
23. 10.1021/acsnano.9b0778910.1021/acsnano.9b07789 ↗
24. 10.1002/adfm.20200243110.1002/adfm.202002431 ↗
25. 10.1002/advs.20190334110.1002/advs.201903341 ↗
26. 10.1039/D0NA00557F10.1039/D0NA00557F ↗
27. Wang H.-S. · Acta Pharm. Sin. · 2020 · 55 · 1511
28. 10.1039/C9CC08498C10.1039/C9CC08498C ↗
29. 10.1021/acs.inorgchem.7b0276110.1021/acs.inorgchem.7b02761 ↗
30. 10.1016/j.micromeso.2020.11053310.1016/j.micromeso.2020.110533 ↗
31. 10.1039/c0cc05002d10.1039/c0cc05002d ↗
32. 10.1039/c3ta10928c10.1039/c3ta10928c ↗
33. 10.1002/anie.20200094710.1002/anie.202000947 ↗
34. 10.1002/ppsc.20130012010.1002/ppsc.201300120 ↗
35. 10.1016/j.ijpharm.2013.01.07310.1016/j.ijpharm.2013.01.073 ↗
36. 10.1016/j.biomaterials.2013.09.00810.1016/j.biomaterials.2013.09.008 ↗
37. 10.1021/acs.analchem.5b0251610.1021/acs.analchem.5b02516 ↗